17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The landscape of multiscale transcriptomic networks and key regulators in Parkinson’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Genetic and genomic studies have advanced our knowledge of inherited Parkinson’s disease (PD), however, the etiology and pathophysiology of idiopathic PD remain unclear. Herein, we perform a meta-analysis of 8 PD postmortem brain transcriptome studies by employing a multiscale network biology approach to delineate the gene-gene regulatory structures in the substantia nigra and determine key regulators of the PD transcriptomic networks. We identify STMN2, which encodes a stathmin family protein and is down-regulated in PD brains, as a key regulator functionally connected to known PD risk genes. Our network analysis predicts a function of human STMN2 in synaptic trafficking, which is validated in Stmn2-knockdown mouse dopaminergic neurons. Stmn2 reduction in the mouse midbrain causes dopaminergic neuron degeneration, phosphorylated α-synuclein elevation, and locomotor deficits. Our integrative analysis not only begins to elucidate the global landscape of PD transcriptomic networks but also pinpoints potential key regulators of PD pathogenic pathways.

          Abstract

          Parkinson’s disease (PD) is characterized by neurodegeneration associated with loss of dopaminergic (DA) neurons and deposition of Lewy bodies. Here, Wang et al. use co-expression network analysis to pinpoint disease pathways and propose reduced expression of STMN2 as a cause of presynaptic function loss in PD.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          alpha-Synuclein is phosphorylated in synucleinopathy lesions.

          The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Importantly, the identification of missense mutations in the alpha-synuclein gene in some pedigrees of familial PD has strongly implicated alpha-synuclein in the pathogenesis of PD and other synucleinopathies. However, specific post-translational modifications that underlie the aggregation of alpha-synuclein in affected brains have not, as yet, been identified. Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions. Furthermore, phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro. These results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Variations in DNA elucidate molecular networks that cause disease.

            Identifying variations in DNA that increase susceptibility to disease is one of the primary aims of genetic studies using a forward genetics approach. However, identification of disease-susceptibility genes by means of such studies provides limited functional information on how genes lead to disease. In fact, in most cases there is an absence of functional information altogether, preventing a definitive identification of the susceptibility gene or genes. Here we develop an alternative to the classic forward genetics approach for dissecting complex disease traits where, instead of identifying susceptibility genes directly affected by variations in DNA, we identify gene networks that are perturbed by susceptibility loci and that in turn lead to disease. Application of this method to liver and adipose gene expression data generated from a segregating mouse population results in the identification of a macrophage-enriched network supported as having a causal relationship with disease traits associated with metabolic syndrome. Three genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits. Our analysis provides direct experimental support that complex traits such as obesity are emergent properties of molecular networks that are modulated by complex genetic loci and environmental factors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Co-regulatory networks of human serum proteins link genetics to disease

              Proteins circulating in the blood are critical for age-related disease processes, however the serum proteome has remained largely unexplored. To this end, 4,137 proteins covering most predicted extracellular proteins, were measured in the serum of 5,457 Icelanders over 65 years of age. Pair-wise correlation between proteins as they varied across individuals, revealed 27 different network modules of serum proteins, many of which were associated with cardiovascular and metabolic disease states as well as overall survival. The protein modules were controlled by cis and trans acting genetic variants; which in many cases were also associated with complex disease. This revealed co-regulated groups of circulating proteins that incorporated regulatory control between tissues and demonstrated close relationships to past, current and future disease states.
                Bookmark

                Author and article information

                Contributors
                zhenyu.yue@mssm.edu
                bin.zhang@mssm.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                20 November 2019
                20 November 2019
                2019
                : 10
                : 5234
                Affiliations
                [1 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, ; 1425 Madison Avenue, New York, NY 10029 USA
                [2 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, ; 1425 Madison Avenue, New York, NY 10029 USA
                [3 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, ; 1470 Madison Avenue, New York, NY 10029 USA
                [4 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Icahn Institute of Genomics and Multi-scale Biology, Icahn School of Medicine at Mount Sinai, ; 1425 Madison Avenue, New York, NY 10029 USA
                Author information
                http://orcid.org/0000-0001-9171-4962
                http://orcid.org/0000-0003-0948-119X
                http://orcid.org/0000-0001-9350-4467
                http://orcid.org/0000-0002-9549-5653
                Article
                13144
                10.1038/s41467-019-13144-y
                6868244
                31748532
                f8aafabe-2380-4a4d-aed6-4dff2f57104c
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 19 January 2019
                : 21 October 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000002, U.S. Department of Health & Human Services | National Institutes of Health (NIH);
                Award ID: P50NS094733
                Award ID: R01NS060809
                Award ID: U01AG046170
                Award ID: RF1AG057440
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: Mount Sinai Seed Funds
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                transcriptomics,synaptic transmission,regulatory networks,parkinson's disease
                Uncategorized
                transcriptomics, synaptic transmission, regulatory networks, parkinson's disease

                Comments

                Comment on this article